Cough as an adverse effect on inhalation pharmaceutical products

Files

Self archived version
final draftDate
2020Author(s)
Unique identifier
10.1111/bph.15197Metadata
Show full item recordMore information
Self-archived article
Citation
Chang, RYK. Kwok, PCL. Ghassabian, S. Brannan, JD. Koskela, HO. Chan, H-K. (2020). Cough as an adverse effect on inhalation pharmaceutical products. British journal of pharmacology, 177 (18) , 4096-4112. 10.1111/bph.15197.Rights
Licensed under
Abstract
Cough is an adverse effect that may hinder the delivery of drugs into the lungs. Chemical or mechanical stimulants activate the transient receptor potential in some airway afferent nerves (C‐fibres or A‐fibres) to trigger cough. Types of inhaler device and drug, dose, excipients and formulation characteristics, including pH, tonicity, aerosol output and particle size may trigger cough by stimulating the cough receptors. Release of inflammatory mediators may increase the sensitivity of the cough receptors to stimulants. The cough‐provoking effect of aerosols is enhanced by bronchoconstriction in diseased airways and reduces drug deposition in the target pulmonary regions. In this article, we review the factors by which inhalation products may cause cough.
Subjects
adverse effect aerosol cough inhalation pharmaceutical productsLink to the original item
http://dx.doi.org/10.1111/bph.15197Publisher
WileyCollections
- Terveystieteiden tiedekunta [1324]